Novo Nordisk Stock 2026 PE Ratio 11 Dividend Yield 44 Is the WeightLossInjection Stock a Bargain Right Now

Summary:

Yes—based on the key metrics, Novo Nordisk is cheaper than it has been in a long time: An estimated P/E ratio of just 11.6 for 2026 is well below the historical ten-year average of over 23, coupled with a dividend yield that at times reached 4.4%. The catch: The stock is still trading about 46% below its all-time high, and the company is battling on several fronts at once. On July 16, 2026, the decisive Phase 3 data for the promising drug CagriSema were locked away—the results could be released at any time. On July 21, 2026, Novo Nordisk sued its archrival Eli Lilly for misleading advertising. On the same day, Trump announced new tariffs on the pharmaceutical industry—but upon closer inspection, these primarily affect generic drug manufacturers and won’t take effect until 2028, leaving Novo Nordisk’s patent-protected core business untouched. Cheap, yes—but is the low price justified in this case?

Key points:

• 2026 P/E ratio (estimated): 11.6 — well below the 10-year average of 23.36

• Dividend yield: currently approx. 3.7%, at times as high as 4.4% during the annual low in March

• CagriSema Phase 3 data withheld since July 16, 2026—publication possible at any time

• Lawsuit filed against Eli Lilly on July 21, 2026, for misleading advertising

• Trump tariffs (July 21): 100–200% on generic drugs starting in 2028/2029 — Wegovy/Ozempic are patent-protected and not directly affected

• Share buyback: up to 15 billion DKK — 44% of the annual target already achieved

• Wegovy pill: fifth global approval, over 3 million U.S. prescriptions since January

• GLP-1 market share in the U.S.: now only about 40% — Eli Lilly at about 60%

• Next quarterly results (Q2): August 5, 2026

How are you going to handle $NOVO B (+0,88 %) now??

Gomerdoc@Gomerdoc

41Min

Up 45% since the start of the year.

Quote:
“Novo Nordisk’s pill hit the market about three months earlier and is said to lead to greater weight loss, which is why doctors have been prescribing it much more frequently than the pill from its U.S. competitor. In June, Novo Nordisk’s drug also received approval in the United Kingdom, and this week it was approved in the EU as well.

Another piece of positive news is that Medicare, the U.S. health insurance program that primarily covers older adults, has been covering most of the costs for weight-loss drugs since the beginning of the month. Eligible patients will then only have to pay a copay of $50 per month. And since many surveys show that most people would rather take pills than give themselves injections on a regular basis, Novo Nordisk could generally regain ground against Eli Lilly.”
Could! Not must.

••

Novo Nordisk Stock 2026: P/E Ratio 11, Dividend Yield 4.4% — Is the Weight-Loss-Injection Stock a Bargain Right Now?